TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21278102

Group type: EXPERIMENTAL
Intervention: Actionable reminders for screening mammography
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Actionable reminders for bone-density exams
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Actionable reminders for HbA1c monitoring
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Actionable reminders for LDL cholesterol monitoring
Number of subjects: 228

Group type: COMPARATOR
Intervention: Actionable reminders
Number of subjects: 228
Study: 19899003

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HFRT) - 57 Gy in 17 fractions (13 fractions of 3 Gy plus 4 fractions of 4.5 Gy)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (CFRT) - 74 Gy in 37 fractions at 2 Gy per fraction for 7.5 weeks
Number of subjects: 91
Study: 17103172

Group type: EXPERIMENTAL
Intervention: Etanercept treatment group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate disease activity group
Number of subjects: 0
Study: 15521667

Group type: EXPERIMENTAL
Intervention: Combination of amphotericin B and endoscopic surgery, associated or not with Caldwell‐Luc surgery
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 11
Study: 12618641

Group type: EXPERIMENTAL
Intervention: Personalized targeted mailing encouraging mammogram screening
Number of subjects: 2458

Group type: COMPARATOR
Intervention: Control group (no mailing)
Number of subjects: 2458

Group type: EXPERIMENTAL
Intervention: Personalized targeted mailing
Number of subjects: 2458
Study: 10214835

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 microg intravaginally every 6 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Misoprostol 200 microg intravaginally every 12 hours
Number of subjects: 100
Study: 8675722

Group type: EXPERIMENTAL
Intervention: Self-report diagnostic measure of GAD based on DSM criteria
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Self-report diagnostic measure of GAD
Number of subjects: 2
Study: 2224121

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) 150 or 300 U/kg via intravenous (IV) bolus
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) 150 or 300 U/kg via subcutaneous (SC) injection
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 78095

Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oestrogen treatment for first 4 years, followed by withdrawal
Number of subjects: 43

Group type: COMPARATOR
Intervention: Oestrogen treatment (first 4 years) vs. Placebo (full 8 years)
Number of subjects: 43
Study: 31277052

Group type: EXPERIMENTAL
Intervention: SI! Program educational intervention (curriculum-based, over 2 or 4 academic years)
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Usual curriculum (control group)
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: SI! Program educational intervention
Number of subjects: 1326
Study: 27470122

Group type: EXPERIMENTAL
Intervention: Enhanced messaging emphasizing safe sleep practices, including avoidance of bedsharing for both SIDS risk reduction and suffocation prevention.
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Standard messaging emphasizing AAP-recommended safe sleep practices, including avoidance of bedsharing for SIDS risk reduction.
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Both groups (enhanced and standard messaging)
Number of subjects: 1194
Study: 25575940

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (100/10, 250/10 or 500/20 μg b.i.d.)
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Fluticasone (100, 250 or 500 μg b.i.d.)
Number of subjects: 1055
Study: 23070786

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group psychotherapy plus open methylphenidate treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Supportive counselling
Number of subjects: 144
Study: 21332722

Group type: EXPERIMENTAL
Intervention: Uniplas LG
Number of subjects: 30

Group type: COMPARATOR
Intervention: Octaplas LG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Uniplas LG and Octaplas LG
Number of subjects: 30
Study: 19101236

Group type: EXPERIMENTAL
Intervention: DM-CKD
Number of subjects: 2218

Group type: COMPARATOR
Intervention: DM-only
Number of subjects: 2218
Study: 17519315

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (SD)
Number of subjects: 10
Study: 15177608

Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moria M2 microkeratome
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bausch & Lomb Automated Corneal Shaper (ACS) microkeratome
Number of subjects: 20
Study: 11475711

Group type: EXPERIMENTAL
Intervention: Philips/Jordan HP735 powered toothbrush
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Braun/Oral-B D7 powered toothbrush
Number of subjects: 3

Group type: COMPARATOR
Intervention: Oral-B Advantage B35 manual toothbrush
Number of subjects: 3
Study: 9924264

Group type: EXPERIMENTAL
Intervention: Bread
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spaghetti
Number of subjects: 12
Study: 7999481

Group type: EXPERIMENTAL
Intervention: Preoperative caudal block
Number of subjects: 25

Group type: COMPARATOR
Intervention: Postoperative caudal block
Number of subjects: 25
Study: 31426772

Group type: EXPERIMENTAL
Intervention: Online patient decision aid (pDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (information leaflet)
Number of subjects: 0
Study: 27879044

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE) - dose-2 (640 mg phenolics/day)
Number of subjects: 49
Study: 24958282

Group type: EXPERIMENTAL
Intervention: DNA-damaging agents
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: p53-positive tumors
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Complete SNP panel
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: ADH1C genotype and p53 status
Number of subjects: 243
Study: 23915589

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB), n = 220
Number of subjects: 458

Group type: COMPARATOR
Intervention: On-pump CABG (ONCAB), n = 238
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 458
Study: 21909836

Group type: EXPERIMENTAL
Intervention: High serum heat shock protein 27 (sHSP27) levels
Number of subjects: 119
Study: 19833904

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 1895

Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 1895
Study: 16157438

Group type: EXPERIMENTAL
Intervention: Sectional matrix system with separation rings
Number of subjects: 71

Group type: COMPARATOR
Intervention: Circumferential matrix system
Number of subjects: 71
Study: 15572639

Group type: EXPERIMENTAL
Intervention: Audio Computer Assisted Self-Interview (ACASI)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Interviewer administered mode (Control)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 700
Study: 11920175

Group type: EXPERIMENTAL
Intervention: Upfront ASCT
Number of subjects: 46

Group type: COMPARATOR
Intervention: Delayed ASCT
Number of subjects: 46
Study: 9055142

Group type: EXPERIMENTAL
Intervention: Eprosartan (200 mg orally twice daily for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matching oral doses for 7 days)
Number of subjects: 0
Study: 8368982

Group type: EXPERIMENTAL
Intervention: Alcohol condition (0.10% BAL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alcohol condition (0.10% BAL to 8 hours)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Older pilots
Number of subjects: 28
Study: 3463349

Group type: EXPERIMENTAL
Intervention: Controlled Drinking (CD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Abstinence (ABST)
Number of subjects: 46
Study: 31216537

Group type: EXPERIMENTAL
Intervention: Combination therapy (tolvaptan and reduced furosemide doses)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional therapy (original furosemide dosage)
Number of subjects: 29
Study: 30216917

Group type: EXPERIMENTAL
Intervention: Methylphenidate, fixed dose
Number of subjects: 602
Study: 26935057

Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B (CpG)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B (CpG) + GM-CSF (GM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CpG + GM
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CpG
Number of subjects: 28
Study: 25264862

Group type: EXPERIMENTAL
Intervention: PLAY Project Home Consultation model
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual community services (CS) only
Number of subjects: 128
Study: 22706128

Group type: EXPERIMENTAL
Intervention: 20 million stem cells (group A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 20 million adipose-derived stem cells plus fibrin glue (group B)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fibrin glue (group C)
Number of subjects: 200
Study: 20150394

Group type: EXPERIMENTAL
Intervention: Oral lipoic acid (1200 mg) - Formulation A
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral lipoic acid (1200 mg) - Formulation B
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral lipoic acid (1200 mg) - Formulation C
Number of subjects: 23

Group type: COMPARATOR
Intervention: Subcutaneous lipoic acid (20 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Subcutaneous lipoic acid (50 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Subcutaneous lipoic acid (100 mg/kg)
Number of subjects: 23
Study: 18333864

Group type: EXPERIMENTAL
Intervention: Maraviroc 100 mg b.i.d. + rifampicin 600 mg q.d.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Maraviroc 100 mg b.i.d. + efavirenz (EFV) 600 mg q.d.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Maraviroc 200 mg b.i.d. + rifampicin or EFV
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg b.i.d. + LPV/r (lopinavir 400 mg + ritonavir 100 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Maraviroc 100 mg b.i.d. + SQV/r (saquinavir 1000 mg + ritonavir 100 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Maraviroc + PI regimens with EFV
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 16078219

Group type: EXPERIMENTAL
Intervention: Levodopa administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9
Study: 16689221

Group type: EXPERIMENTAL
Intervention: Automated segmentation and thickness mapping of articular cartilage using MR images
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MR-based assessment of tissue engineered grafts
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MR imaging of bovine and porcine cadaveric knees with artificial cartilage lesions
Number of subjects: 3
Study: 10412882

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg OD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7750917

Group type: EXPERIMENTAL
Intervention: GH 8 IU/m2 3 times/week
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: GH 4 IU/m2 6 times/week
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol 100 ng/kg body weight/day (for patients older than 12 years)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (untreated adult Dutch patients with Turner syndrome)
Number of subjects: 54
Study: 2256009

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Silver acetate chewing gum
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Ordinary chewing gum
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 496
Study: 540429

Group type: EXPERIMENTAL
Intervention: alpha‐receptor blockade (phentolamine 10 mg intravenously)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: combined alpha‐ and beta‐ receptor blockade (labetalol 100 mg intravenously)
Number of subjects: 27
Study: 31641967

Group type: EXPERIMENTAL
Intervention: PBMT + nonsurgical periodontal treatment (NSPT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: nonsurgical periodontal treatment (NSPT)
Number of subjects: 22
Study: 31538180

Group type: EXPERIMENTAL
Intervention: Atomoxetine 40 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 28538312

Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT) for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 20
Study: 25628380

Group type: EXPERIMENTAL
Intervention: Articulated ankle‐foot orthosis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rigid carbon fiber footplate attached to a foot orthosis
Number of subjects: 18
Study: 23692383

Group type: EXPERIMENTAL
Intervention: 25 mg diclofenac HPβCD
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac HPβCD
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac HPβCD
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 21976257

Group type: EXPERIMENTAL
Intervention: Factor seven for acute hemorrhagic stroke (FAST)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Careful reduction of systolic blood pressure (SBP) by 1–10% in the first 24 h
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Neurological worsening within the first 72 h
Number of subjects: 821
Study: 19237898

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin (6 patients)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Bolus dosing of piperacillin (7 patients)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Bolus dosing of piperacillin
Number of subjects: 13
Study: 17541052

Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dynamic supportive treatment
Number of subjects: 90
Study: 15289715

Group type: EXPERIMENTAL
Intervention: Active HVPC electrotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham HVPC (control)
Number of subjects: 0
Study: 11769819

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 188

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 188
Study: 9241693

Group type: EXPERIMENTAL
Intervention: Humidified hyperbaric oxygen
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dry hyperbaric oxygen
Number of subjects: 13
Study: 8504970

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) enemas
Number of subjects: 63

Group type: COMPARATOR
Intervention: bismuth citrate-carbomer enemas
Number of subjects: 63
Study: 3691321

Group type: EXPERIMENTAL
Intervention: Dextrose 8.1 kcal per kg per day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dextrose 30.7 kcal per kg per day
Number of subjects: 8
Study: 29961816

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 26645392

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 1556
Study: 24195864

Group type: EXPERIMENTAL
Intervention: 100 mg FeSO4
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22170382

Group type: EXPERIMENTAL
Intervention: Community mobilization (CM) and mobile voluntary counseling and testing (MVCT) with edutainment during evening hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community mobilization (CM) with edutainment
Number of subjects: 0
Study: 20420761

Group type: EXPERIMENTAL
Intervention: Sucralose (4 mM in 0.9% saline)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 10
Study: 16942867

Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 16
Study: 16259175

Group type: EXPERIMENTAL
Intervention: Low-intensity ultrasound therapy (20 minutes daily for six weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (inactive ultrasound device)
Number of subjects: 16
Study: 12070676

Group type: EXPERIMENTAL
Intervention: Balneotherapy (20-min bathing, once a day, five times per week for 3 weeks, total of 15 sessions)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 42
Study: 10818663

Group type: EXPERIMENTAL
Intervention: Brief psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7674504

Group type: EXPERIMENTAL
Intervention: Risk factor modification (very low‐fat vegetarian diet, mild to moderate exercise, stress management, group support)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care (antianginal therapy)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Risk factor modification
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study: 2206076

Group type: EXPERIMENTAL
Intervention: Oral terbutaline, 2.5 to 5 mg every 3 to 4 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral magnesium oxide, 200 mg every 3 to 4 hours
Number of subjects: 50
Study: 6930206

Group type: EXPERIMENTAL
Intervention: Labetalol (400 mg/day first month, average 585 mg/day second month)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Propranolol (160 mg/day first month, average 234 mg/day second month)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Labetalol (higher dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Labetalol with diuretic
Number of subjects: 13

Group type: COMPARATOR
Intervention: Propranolol (long term therapy)
Number of subjects: 13
Study: 31365109

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment aimed at decreasing systolic BP by 10%-25% within the first 24 hours, achieving systolic BP <140 mm Hg and diastolic BP <90 mm Hg within 7 days, and maintaining this level during hospitalization.
Number of subjects: 4071

Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment
Number of subjects: 4071

Group type: COMPARATOR
Intervention: Control group (discontinued all antihypertensive medications)
Number of subjects: 4071
Study: 28647458

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 205
Study: 25774975

Group type: EXPERIMENTAL
Intervention: Abductor hop
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Jumping jacks (JJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Frontal kick
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cross-country skiing (CCS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stationary running
Number of subjects: 12
Study: 23766737

Group type: EXPERIMENTAL
Intervention: PlayWisely program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 19734256

Group type: EXPERIMENTAL
Intervention: Iyengar Yoga (IY) for 12 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) for 12 weeks
Number of subjects: 57
Study: 19303675

Group type: EXPERIMENTAL
Intervention: Low cost behavioral prevention program in preschool settings
Number of subjects: 2658

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2658
Study: 17143194

Group type: EXPERIMENTAL
Intervention: Aliskiren monotherapy (75, 150 or 300 mg)
Number of subjects: 2776

Group type: EXPERIMENTAL
Intervention: Combination of aliskiren (300 mg) and HCTZ (25 mg)
Number of subjects: 2776

Group type: COMPARATOR
Intervention: HCTZ monotherapy (6.25, 12.5 or 25 mg)
Number of subjects: 2776

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2776
Study: 15606470

Group type: EXPERIMENTAL
Intervention: Prolate anterior surface IOL (Tecnis Z9000, Pharmacia)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Biconvex spherical surface IOL (CeeOn 911 A, Pharmacia)
Number of subjects: 12
Study: 11841195

Group type: EXPERIMENTAL
Intervention: Flunisolide 500 microg administered twice daily by nebulizer for 4 weeks
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Budesonide 500 microg administered twice daily by nebulizer for 4 weeks
Number of subjects: 133
Study: 9743401

Group type: EXPERIMENTAL
Intervention: Paralysis with vecuronium
Number of subjects: 7

Group type: COMPARATOR
Intervention: No muscle relaxants (unparalyzed)
Number of subjects: 7
Study: 8001599

Group type: EXPERIMENTAL
Intervention: New acenocoumarol tablet formulation (12 mg single oral dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: New acenocoumarol tablet formulation
Number of subjects: 8
Study: 3892994

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (Heparin Leo 5000 I.U. subcutaneously twice daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Graded compression stockings (TED stockings, Kendall Co.)
Number of subjects: 112
Study: 30897995

Group type: EXPERIMENTAL
Intervention: apo(a) production rate (PR)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: apo(a) fractional catabolic rate (FCR)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: apo(a) PR
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: apo(a) FCR
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: apo(a) PR and FCR
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: apo(a) PR and isoform size
Number of subjects: 63
Study: 29678962

Group type: EXPERIMENTAL
Intervention: Letter from GP outlining importance of asthma medication (delivered in late July)
Number of subjects: 12179

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 12179

Group type: EXPERIMENTAL
Intervention: Letter from GP
Number of subjects: 12179
Study: 26656775

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 54
Study: 24281825

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Training (CMT)
Number of subjects: 16